What 310.ai does

310.ai is a San Francisco-based generative AI company founded in 2022 that builds transformer-based foundation models for de novo protein design. The company's flagship product, MP4 (Molecule Programming Model), generates high-quality proteins from natural language text prompts by compressing approximately 4 billion years of evolutionary data into a generative AI system. The platform is complemented by the MP Repo (1,053+ AI-designed proteins) and MP EC Repo (6,590+ AI enzymes covering 100% of top-level EC enzyme classes, including 725 never-before-seen discoveries). The company also references development of a next-generation MP5 model.

The technology stack is built on AMD Instinct MI300 Series GPUs with AMD ROCm software, alongside partnerships with NVIDIA and AWS for additional compute infrastructure. In laboratory validation published in November 2024, MP4 achieved an 84% protein expression rate, substantially exceeding the 20-30% rate typical of non-AI methods. Subsequent published results include AI-designed peptides where 67% outperformed GLP-1 in binding assays compared to roughly 0.1% for traditional approaches, and a 214-amino-acid enzyme with potential applications for heart disease. The model accepts text prompts and outputs protein sequences annotated with structured metrics including amino acid composition, PLDDT structural confidence scores, and functional similarity measures.

310.ai serves biotechnology, pharmaceutical, and academic research segments through direct enterprise partnership engagements, delivering the complete AI stack (infrastructure plus models) rather than a self-serve product. Pricing is not publicly disclosed. The company has raised approximately $3.78 million across two funding rounds, with disclosed investors Cota Capital, Ascend Vietnam Ventures, and E14 Fund. Co-founders Koosh Azimian (CEO, former Facebook Staff AI Engineer) and Kathy Y. Wei, Ph.D. (CSO, Stanford-trained computational protein designer and former Amgen researcher) lead technical and business operations.

Name

310.ai

Legal name

310.ai

Website

https://310.ai

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

310.ai is a San Francisco-based generative AI company building a proprietary transformer foundation model (MP4) that generates de novo proteins from text prompts, serving biotech, pharmaceutical, and academic research customers through direct enterprise partnerships.

Ownership category

akta.pro rank

Product category

AI Protein Design / Generative Biology

NAICS

Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)

Keywords

• Generative protein design
• De novo protein generation
• AI protein engineering
• Molecule programming models
• Computational biology AI

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

310.ai develops MP4, a transformer-based foundation model that generates high-quality de novo proteins from natural language text prompts, compressing 4 billion years of evolutionary data into a generative AI system. The offering includes the MP Repo (1,052+ AI-designed proteins including enzymes, scaffolds, and hormones) and the MP EC Repo (6,590+ AI-generated enzymes covering 100% of top-level EC enzyme classes, with 725 never-before-seen discoveries). The model achieves an 84% lab expression rate, vastly surpassing the 20–30% rates of traditional non-AI methods.

Product overview

310.ai is a California-based generative AI startup building an AI operating system for life sciences. The core offering consists of the MP4 (Molecule Programming Model), a transformer-based foundation model that generates de novo proteins from text prompts, complemented by the MP Repo (1,052+ AI-designed proteins) and the MP EC Repo (6,590+ AI enzymes covering 100% of enzyme classes). The company also conducts lab testing achieving 84% expression rates and has developed AI-designed peptides that outperform GLP-1 in binding assays.

Differentiator

Problem solved

Functional benefit

Products and services

• MP4 (Molecule Programming Model) Transformer-based foundation model for molecule programming that generates high-quality de novo proteins from text prompts, targeting applications in medicine, industry, and environmental engineering. Achieves an 84% lab expression rate and is the core AI engine powering 310.ai's programmable biology platform.
• MP Repo (Protein Repository)

Quantifiable outcome

• 84% lab expression rate achieved by MP4, compared to 20-30% for non-AI methods
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• AMDcoreTechnology or Integration · 18 February 2026310 AI utilizes AMD Instinct MI300 Series GPUs and AMD ROCm software to develop and run its AI models for protein design. This hardware partnership enables the computational infrastructure needed for training and deploying large-scale generative AI models for molecular programming.
• NVIDIAcoreTechnology or Integration310.ai partners with NVIDIA for AI computing infrastructure. NVIDIA is listed as a key technology partner alongside AMD and AWS. The partnership provides GPU computing resources for training and running the company's generative AI models for protein design.
• Amazon Web ServicescoreTechnology or Integration310.ai partners with AWS for cloud computing infrastructure. AWS is listed as a key technology partner alongside NVIDIA and AMD, providing cloud infrastructure support for the company's AI model training and deployment.

Recent moves6 records

Expansion highlights6 records

Direct peers

• Profluent: Applies large language model approaches to protein design, generating novel protein sequences with desired functions. Directly comparable technology stack and target customer segments in biotech and pharma.
• Isomorphic Labs: Alphabet/DeepMind spin-out building AI foundation models for drug discovery and protein structure/design. The most direct competitor to 310.ai, with substantially more capital and a deeper pharma partnership base.
• Cradle: AI platform for protein engineering, helping biotech and pharma partners design and optimize proteins. Direct overlap in generative biology tooling and enterprise partnership GTM motion.
• Generate Biomedicines: Generative biology company creating novel protein therapeutics using machine learning. Closely aligned mission of programmable protein design with strong pharma backing.

Broad incumbents

• Recursion Pharmaceuticals: Publicly listed AI-driven drug discovery company with broad platform spanning image-based phenomics and target discovery. Operates at much larger scale and competes for enterprise pharma AI partnerships.
• Schrödinger: Computational chemistry and molecular simulation platform used across pharma R&D. Broader portfolio than 310.ai but competes for the same computational biology budget at pharma customers.
• AbCellera: Antibody discovery platform combining wet-lab high-throughput screening with ML. Larger and more established; relevant comparable for biotech-pharma partnership model and antibody/peptide design adjacent work.
• XtalPi: AI-driven drug discovery company combining physics-based modeling, ML, and robotic experimentation. Operates at greater scale globally and competes for pharma AI-discovery partnerships.

Emerging players

• EvolutionaryScale: AI research company developing frontier foundation models for biology, including protein generation. Less commercial maturity than 310.ai but represents a technical adjacent in generative biology.
• Insitro: ML-driven drug discovery platform combining data generation and predictive models. Less focused on de novo protein design but overlaps in AI-for-biology customer base and enterprise pharma GTM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 310.ai